ASCO 2022 | A subgroup analysis of the SECOMBIT trial

Paolo Ascierto, MD, National Tumor Institute, Milan, Italy, presents findings from the phase II SECOMBIT trial (NCT02631447), which assessed the best sequential strategy for patients with untreated, metastatic BRAFV600 melanoma. One arm received encorafenib and binimetinib (targeted therapy) followed by ipilimumab and nivolumab (immunotherapy), whereas another subsequently received another course of targeted therapy (the “sandwich” strategy). A third arm initially received immunotherapy followed by targeted therapy. The arm receiving immunotherapy followed by targeted therapy as well as the “sandwich” strategy resulted in favourable overall survival rates. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.